In this case study, a patient with HCV mono-infection had missed 21 days of Direct-Acting Antiviral (DAA) therapy. What to do? A clinician called the AETC National Clinician Consultation Center (NCCC) for advice, asking: "Should they finish the missed doses or extend therapy?"
Read the response in NCCC's Promising Practices & Pearls: HCV Treatment Interruption, the AETC ShareSpot, 9/8/23.